Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The burden of atrial fibrillation (AF) is increasing worldwide; however, most existing data on AF epidemiology are from Western regions. According to our analyses, the estimated absolute prevalence of AF in the Asia–Pacific region in 2023 was approximately 80 million, which is much higher than has been calculated for other global regions.
In this Review, Münzel and colleagues describe the adverse effects of soil and water pollution, including heavy metal, pesticide, and microplastic and nanoplastic pollution, on cardiovascular health and provide an overview of the eco-disruptive causes of this pollution.
John C. Lin and colleagues explore the history of racial disparities in cardiovascular outcomes and discuss the landmark findings of the CARDIA study and its contribution to the minority stress model.
The 20th anniversary of Nature Reviews Cardiology comes at a time of exciting innovation for cardiovascular research and clinical cardiology, with the advent of nucleic acid-targeted therapeutics, applications of artificial intelligence, promotion of a healthy cardiovascular exposome, personalization of medicine, and recognition of the importance of diversity, equity and inclusion in health care.
A study using advanced single-cell technologies has broadened our understanding of the diversity and complexity of brain endothelial cells by uncovering new endothelial subtypes and transcriptional patterns. These findings offer insights into potential therapeutic targets and emphasize the need for further research on vascular lineages and neurovascular interactions.
In this Review, the authors describe the bidirectional crosstalk between lysosome biology and immune cell function and polarization, focusing on immunometabolic reprogramming in the context of atherosclerosis and highlighting knowledge gaps and potential therapeutic strategies targeting immune cell lysosomes.
Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.
In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an assist device or stroke at 1 year after the procedure, according to findings from the MATTERHORN trial.
In the NOTION-3 trial, percutaneous coronary intervention reduced the occurrence of major adverse cardiac events compared with conservative treatment in patients who were undergoing transcatheter aortic valve implantation for severe aortic stenosis and who had stable coronary artery disease.
The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress 2024.
A single combined measurement of high-sensitivity C-reactive protein, LDL-cholesterol and lipoprotein(a) levels in plasma predicts incident cardiovascular events among women over a 30-year follow-up period, according to a new study.
Cardiomyocytes can activate the type I interferon response in the infarct border zone after myocardial infarction, indicating that the type I interferon pathway, in addition to its well-established role in antiviral responses, is also involved in cardiac injury.
New research suggests that the presence of clonal haematopoiesis is unidirectionally associated with the development of atherosclerosis and that colchicine holds potential therapeutic value.
The gut microbiota has emerged as a risk factor that affects thrombotic phenotypes in several cardiovascular diseases. In this Review, Reinhardt and colleagues discuss the link between the gut microbiota, its metabolites and thromboembolic diseases, and summarize potential therapeutic interventions to modulate the gut microbiota.
Genetic testing for inherited cardiac disease has become part of routine clinical care. In this Review, Verdonschot et al. provide an overview of the reproductive options in the context of monogenic cardiac diseases, with a focus on preimplantation genetic testing, to prepare health-care professionals for discussions with their patients.
In this Review, Shi and co-workers summarize the available evidence on the role of eosinophils in cardiovascular diseases, highlighting differences between preclinical and clinical findings and placing clinical data in the context of experimental data to discuss potential pathogenic or protective roles of eosinophils in different cardiovascular disease settings.
The immune response is not unlike a game of chess, with white and black pieces playing opposing roles and orchestrating an opening, a middle and an endgame of innate immunity, adaptive immunity and resolution, respectively. After decades of research, the study of atheroimmunology has brought the first therapeutics to the clinic. Can we resynchronize the immune system in atherosclerosis and save the king?
The pathophysiology of heart failure with preserved ejection fraction (HFpEF) remains poorly understood. In this Review, Redfield and colleagues highlight the importance of studying human cardiac tissue in HFpEF, discuss sources, challenges and methods for studying human myocardial samples, summarize pathophysiological insights derived from studies of human myocardium in HFpEF and outline knowledge gaps to guide future research.
